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OBJECTIVE — Sustained hyperglycemia is associated with low cellular levels of the antiox-
idant glutathione (GSH), which leads to tissue damage attributed to oxidative stress. We tested
the hypothesis that diminished GSH in adult patients with uncontrolled type 2 diabetes is
attributed to decreased synthesis and measured the effect of dietary supplementation with its
precursors cysteine and glycine on GSH synthesis rate and oxidative stress.
RESEARCH DESIGN AND METHODS — We infused 12 diabetic patients and 12
nondiabetic control subjects with [
2H2]-glycine to measure GSH synthesis. We also measured
intracellular GSH concentrations, reactive oxygen metabolites, and lipid peroxides. Diabetic
patients were restudied after 2 weeks of dietary supplementation with the GSH precursors
cysteine and glycine.
RESULTS — Compared with control subjects, diabetic subjects had signiﬁcantly higher fast-
ing glucose (5.0  0.1 vs. 10.7  0.5 mmol/l; P  0.001), lower erythrocyte concentrations of
glycine (514.7  33.1 vs. 403.2  18.2 mol/l; P  0.01), and cysteine (25.2  1.5 vs. 17.8 
1.5 mol/l; P  0.01); lower concentrations of GSH (6.75  0.47 vs. 1.65  0.16 mol/g Hb;
P  0.001); diminished fractional (79.21  5.75 vs. 44.86  2.87%/day; P  0.001) and
absolute (5.26  0.61 vs. 0.74  0.10 mol/g Hb/day; P  0.001) GSH synthesis rates; and
higher reactive oxygen metabolites (286  10 vs. 403  11 Carratelli units [UCarr]; P  0.001)
and lipid peroxides (2.6  0.4 vs. 10.8  1.2 pg/ml; P  0.001). Following dietary supplemen-
tation in diabetic subjects, GSH synthesis and concentrations increased signiﬁcantly and plasma
oxidative stress and lipid peroxides decreased signiﬁcantly.
CONCLUSIONS — Patients with uncontrolled type 2 diabetes have severely deﬁcient syn-
thesis of glutathione attributed to limited precursor availability. Dietary supplementation with
GSH precursor amino acids can restore GSH synthesis and lower oxidative stress and oxidant
damage in the face of persistent hyperglycemia.
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D
iabetes is the leading worldwide
cause of blindness, end-stage renal
disease, and amputations. Diabetes
also is associated with an elevated risk of
macrovascular complications including
myocardial ischemia and strokes. Al-
thoughmultiplepathwaysareinvolvedin
mediating tissue damage, including the
polyol pathway, advanced glycation end
product formation, protein kinase C acti-
vation, and the hexosamine pathway, a
common feature is increased oxidative
stress marked by elevated levels of reac-
tive oxygen species (ROS) (1). The ability
of a cell to resist damage caused by oxida-
tivestressisdeterminedbythecapacityof
an array of antioxidant defense systems,
among which reduced glutathione (GSH)
is the most ubiquitous and abundantly
available within human cells. GSH is a
tripeptide synthesized from glutamate,
cysteine, and glycine in two steps cata-
lyzed by -L-glutamyl-L-cysteine:glycine
ligase and glutathione synthetase. Diabe-
tes is associated with decreased cellular
glutathione concentrations (2–5), but the
cause of GSH deﬁciency currently is
unknown.
Oxidative stress and ROS formation
are markedly increased by uncontrolled
hyperglycemia (2,6); conversely, lower-
ing blood glucose concentrations lowers
oxidative stress (7,8). Decreased oxida-
tive stress could be an important mecha-
nism whereby glycemic control
diminishes the incidence of diabetic mi-
crovascular complications (9,10). How-
ever, there are practical limitations to
blunting oxidative stress through glyce-
mic control alone, despite strenuous at-
tempts to implement evidence-based
guidelines, a majority of patients are un-
able to achieve the glycemic goals (e.g.,
A1C 7%) advocated by the American
Diabetes Association (11). Consequently,
despite the clear message of landmark tri-
alssuchastheDiabetesControlandCom-
plications Trial and the UK Prospective
Diabetes Study regarding the need for ex-
cellentglycemiccontrol,diabetesremains
the leading cause of blindness, renal fail-
ure, and amputations. There is an urgent
needfornovelstrategiestoreducetherate
of diabetes complications in patients un-
able to achieve stable glycemic control.
We therefore investigated whether oxida-
tive stress associated with low levels of
GSH could be ameliorated through the
alternative strategy of increasing cellular
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controlled hyperglycemia.
Because circulating concentrations of
a protein depend on the balance between
its rates of production and consumption,
we hypothesized that GSH deﬁciency in
uncontrolled diabetes occurs because of
diminished synthesis. We further hy-
pothesized that short-term dietary sup-
plementation of two key amino acid
precursors of GSH, glycine and cysteine,
would increase intracellular GSH synthe-
sis and concentrations and thus lower ox-
idative stress, despite continuing
hyperglycemia. To test these hypotheses,
we used stable isotope methods to com-
pare GSH synthesis rates and concentra-
tions within erythrocytes, as well as
plasma markers of oxidant damage, in
adultpatientswithpoorlycontrolledtype
2 diabetes matched to nondiabetic con-
trol subjects. The diabetic patients were
studiedbeforeandafter14daysofdietary
supplementation with cysteine and
glycine.
RESEARCH DESIGN AND
METHODS— The study was ap-
proved by the institutional review board
for Human Studies at Baylor College of
Medicine. Twelve adults with uncon-
trolled type 2 diabetes (A1C 8–10%) and
12 nondiabetic control subjects matched
for age, sex, and BMI were recruited. In-
formed consent was obtained from all
subjects. All subjects were free of thyroid
disorders, hypercortisolemia, liver or re-
nal impairment and malignancy, and had
noinfectionsormajorillnessesduringthe
preceding 6 months. All had sedentary
lifestyles and none consumed unusual di-
ets or dietary supplements. All subjects
were instructed to abstain from alcoholic
beverages during the study.
Allpatientsreceiveddiabeticmanage-
ment from their primary physicians. To
prevent acute swings of blood glucose,
and to achieve comparable glycemic lev-
els before and after supplementation with
cysteine and glycine, we excluded pa-
tients receiving insulin therapy and re-
cruited only subjects who recently were
diagnosedandwerebeingtreatedwithei-
ther lifestyle modiﬁcation or oral antidia-
betic agents.
Subjects were studied in the adult
generalclinicalresearchcenter(GCRC)of
the Baylor College of Medicine. After
measurement of blood counts, glucose
concentrations, glycosylated hemoglo-
bin, and liver and renal proﬁles, subjects
participated in the ﬁrst infusion study.
The GCRC protocol consisted of intrave-
nous infusions of stable isotopes to mea-
sure GSH synthesis in the fasted state. All
subjectswerestudiedunderbaselinecon-
ditions; only the diabetic subjects were
studied again after 14 days of dietary sup-
plementation with 0.81 mmol/kg/day of
cysteine (given as n-acetylcysteine) and
1.33 mmol/kg/day of glycine. Subjects
were asked to consume their usual habit-
ual diets from 2 weeks before beginning
the study to the end of the study period.
Sterile solutions of [
2H2]glycine
(Cambridge Isotope Laboratories,
Woburn, MA) were prepared. After a
10-h fast, subjects were admitted to the
GCRC for the study, where two intrave-
nous catheters were inserted into superﬁ-
cial veins for continuous infusion of the
tracersolutionsandbloodsampling.After
abasalbloodsamplewasdrawn,aprimed
constant intravenous infusion of
[
2H2]glycine(primedose20mol/kg;in-
fusion dose 15 mol/kg/h) was main-
tained for 8 h. Additional blood samples
were taken at 2, 3, 4, 5, 6, 7, and8hf o r
measurement of erythrocyte GSH derived
glycine isotopic enrichments.
The primary outcome variables were
fractional and absolute synthesis rates of
GSH within erythrocytes, erythrocyte
GSH, cysteine, glycine and glutamate
concentrations, plasma lipid peroxide
levels, and plasma oxidative stress mea-
sured as reactive oxygen metabolites.
Sample analyses
Blood chemistries. Baseline plasma
sampleswerealiquottedintotubesforthe
various assays, and stored at 80°C for
later analyses. Hemoglobin, reactive oxy-
gen metabolites (DROMS), (Diacron In-
ternational, Grosetto Italy), plasma
chemistries, and lipid peroxides were
measured.
Erythrocyte GSH analyses. Erythro-
cyte GSH concentration and isotopic en-
richment of GSH were measured as
described next (12). Brieﬂy, duplicate ali-
quots of 1 ml whole blood were centri-
fuged to separate packed cells and
measure GSH and glutamate, cysteine,
andglycine,respectively.Theﬁrstaliquot
of packed erythrocytes was washed thrice
with normal saline and 1 ml of monobro-
mobimane (MBB) buffer (5 mmol/l MBB,
17.5 mmol/l Na2EDTA, 50 mmol/l potas-
sium phosphate, 50 mmol/l serine, and
50 mmol/l boric acid) was added. Cells
were immediately lysed by rapid freeze-
thaw with liquid nitrogen, and the eryth-
rocyte-MBB buffer mixture was shaken
and left in the dark at room temperature
for 20 min for development of the GSH-
MBB derivative. After adding 0.5 ml of
20% perchloric acid, the sample was cen-
trifuged, and the supernatant containing
the MBB derivative was sealed and frozen
at 80°C for later analysis of GSH. Con-
centrations of GSSG were measured by
ﬁrst converting oxidized glutathione to
reducedglutathionewiththeadditionofa
reducing agent (5 mmol/l dithiothreitiol)
and measuring this as total GSH; the cal-
culated difference between total GSH and
reduced GSH is the concentration of
GSSG.
Erythrocyte GSH was isolated as an
red blood cell-free aliquot, and the con-
centration measured high-performace
liquid chromatography (Waters, Milford,
MA) using a 717 Plus autosampler com-
plexed to a 2475 ﬂuorescent detector and
equipped with a reverse-phase ODS Hy-
persilcolumn(5m,4.6200mm;Wa-
ters). Elution of GSH was accomplished
with a 3–13.5% acetonitrile linear gradi-
ent in 1% acetic acid (pH 4.25) at a ﬂow
rate of 1.1 ml/min. The GSH eluate was
collected using a fraction collector, dried,
and hydrolyzed for4hi n4m ol/l HCl at
110°C.
Erythrocyte free amino acids
A 1-ml aliquot of blood was centrifuged,
anderythrocyteswerethenwashedthrice
with 3 ml sodium chloride solution (9
g/l). RBCs were then lysed by freeze-thaw
actionwiththeuseofliquidnitrogen,and
cellular proteins were precipitated by us-
ing 10% perchloric acid solution. After
centrifugation, the supernatant ﬂuid was
used for erythrocyte free amino acid anal-
ysis. Before derivatization for gas chro-
matographic–mass spectrometric
analysis, erythrocyte-free glycine was iso-
lated by cation-exchange (Dowex 200;
Bio-Rad Laboratories, Hercules, CA)
chromatography. Samples of glycine de-
rived from erythrocyte glutathione and
plasma and erythrocyte-free glycine sam-
ples were converted to the n-propyl ester,
heptaﬂuorobutyramide derivative. The
tracer-to-traceeratioforglycineinvarious
samples was determined by negative
chemical ionization gas chromatograph-
ic–mass spectrometric analysis with se-
lective monitoring of ions at mass-to-
charge ratios of 293–295 on an Agilent
6980 gas chromatograph complexed to a
5973 mass spectrometer (Agilent Tech-
nologies, Wilmington, DE). Erythrocyte
amino acid concentrations were deter-
mined by high-performace liquid chro-
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system (Millipore, Milford, MA).
Oxidant markers
To assess the level of oxidative stress, the
derivativesofDROMsweredeterminedin
serum. Brieﬂy, plasma is reacted with an
acidic acetate buffer (pH 4.8), which lib-
erates transition metal ions that catalyze
the decomposition of the hydroperoxides
to alkoxy and peroxyl radicals. These
newly formed radicals in turn oxidize the
spectrophotometric marker (N,N-
diethyl-p-phenylenediamine), which is
detectable by absorption at 505 nm as
UCarr(where1UCarrisequalto0.8mg/l
hydrogen peroxide).
Lipid peroxides
Brieﬂy, this was measured using freshly
prepared buffers containing ammonium
ferrous sulfate, xylenol orange, H2SO4,
BHT in 90% vol/vol methanol, and triph-
enylphosphine in methanol. Standard so-
lutions were made using 30% H2O2.
Heparinized blood was centrifuged, and
10 l of 10 mmol/l TPP solution was
added to 90 l of plasma (control vials)
then 10 l of methanol was added (test
vials), and this solution was incubated at
room temperature for 30 min. After add-
ing appropriate buffers, each vial was in-
cubated at room temperature for 30 min,
centrifuged,andtheabsorbanceofthesu-
pernatantwasdeterminedbyspectropho-
tometry. The hydroperoxide content was
determined from test controls and as-
sayed against the standard curve (13).
Calculations
The fractional synthesis rate (FSR) of
erythrocyteGSH(FSRGSH)wascalculated
according to the precursor-product equa-
tion: FSRGSH (%/day)  (IRt7  IRt5)/
(IRrbc  1,200/t7  t5), where IRt7  IRt5
istheincreaseintheisotoperatiooferyth-
rocyte GSH-bound glycine between the
ﬁfth and seventh hours of infusion, when
the isotope ratio of erythrocyte-free gly-
cine,IRrbc,hadreachedasteadystate.The
units of FSR are percentage per day (%/
day). The absolute synthesis rate (ASR) of
erythrocyte GSH per day was calculated
as follows: ASR  erythrocyte GSH con-
centration  FSR. The units of ASR are
expressed as micromols of GSH per gram
of hemoglobin per day.
Statistics
Data are expressed as means  SE. An
independent unpaired t test was used to
compute differences in means between
the diabetic group presupplementation
and the control group and also between
the diabetic group postsupplementation
and the control group. Differences in out-
come measures in the diabetic patients
studied pre- and postsupplementation
was determined using a paired t test. Data
analysis was performed with the Statmate
statistical software (GraphPad Software,
LA Jolla, CA). Results were considered to
be statistically signiﬁcant at P  0.05.
RESULTS
Baseline characteristics
The average ages of the control and dia-
betic subjects were 50.4  3.8 and
51.0  3.1 years, respectively (Table 1).
There were no group differences in BMI,
hematocrit and hemoglobin concentra-
tions, renal functions, or liver enzymes.
The control subjects were euglycemic,
whereas the diabetic subjects had signiﬁ-
cantly higher fasting glucose concentra-
tionsandglycosylatedhemoglobin.There
were no differences in hematologic pa-
rameters, renal function, or liver enzymes
before or after cysteine and glycine sup-
plementation in the diabetic group.
Erythrocyte GSH kinetics and
concentration of glycine, cysteine,
glutamate, and GSH
Compared with nondiabetic control sub-
jects, subjects with poorly controlled dia-
betes had 73.8% lower erythrocyte-
reduced glutathione concentrations
(6.750.47vs.1.650.16mol/gHb;
P  0.001) (Fig. 1A) and higher concen-
trations of erythrocyte-oxidized GSSG
(0.100.01vs.0.330.07mol/gHb;
P  0.05). Compared with control sub-
jects, total glutathione concentrations
(6.750.47vs.1.650.16mol/gHb;
P  0.001) and the ratio of GSH to GSSG
were both signiﬁcantly lower in diabetic
subjects (59.15  4.12 vs. 6.30  1.30;
P  0.001). Diabetic subjects also had
43.4%slowerGSHFSR(79.215.75vs.
44.86  2.87%/day; P  0.001) and
85.5% slower ASR (5.26  0.61 vs.
0.74  0.10 mol/g Hb/day; P  0.001)
(Figs. 1B and C). Compared with control
subjects, diabetic subjects also had signif-
icantly lower RBC concentrations of gly-
cine (514.7.7  33.1 vs. 403.2  18.2
mol/l; P  0.01) and cysteine (25.2 
1.5 vs. 17.8  1.5, mol/l; P  0.01) but
not glutamate (530.1  88.3 vs. 451.5 
120.7 mol/l; P  0.61).
Table 1—Clinical, hematological, and biochemical characteristics of nondiabetic control sub-
jects and pretreatment and posttreatment data for subjects with type 2 diabetes
Parameters
Nondiabetic
subjects
Diabetic
subjects
pretreatment
Diabetic
subjects
posttreatment P
Age (years) 50.4  3.8 51.0  3.1 51.0  3.1 NS
BMI (kg/m
2) 28.0  0.9 30.4  0.7 30.0  0.9 NS
Hemoglobin (g/l) 14.2  1.8 13.7  1.4 13.7  1.2 NS
Fasting plasma glucose (mmol/l) 5.0  0.1 10.7  0.5* 10.6  0.4 0.001*
A1C (%) 5.5  0.1 9.1  0.2* 9.0  0.2 0.001*
Blood urea nitrogen (mmol/l) 5.3  0.3 5.4  0.6 5.4  0.4 NS
Creatinine (mol/l) 88.4  3.4 79.6  4.2 79.6  3.8 NS
Alanine aminotransferase (U/l) 20.4  1.2 23.8  5.0 24.4  4.4 NS
Aspartate aminotransferase (U/l) 17.6  1.4 18.2  2.4 17.9  2.6 NS
Glutamate (mmol/l) 530.1  88.3 451.5  120.7 482.4  98.2 NS
Cysteine (mol/l) 25.2  1.5 17.8  1.5* 25.5  1.9† 0.01*
0.05†
Glycine (mol/l) 514.7  33.1 403.2  18.2* 521.6  19.4† 0.01*
0.01†
DROMs (UCarr) 286  10 403  11* 359  10†‡ 0.001*
0.05†
0.01‡
Lipid peroxide (mol/l) 2.6  0.4 10.8  1.2* 6.2  0.9†‡ 0.001*
0.01†
0.05‡
*Nondiabetic control subjects versus diabetic subjects: pre-treatment. †Diabetic subjects: pretreatment
versus posttreatment. ‡Diabetic subjects: posttreatment versus nondiabtic control subjects.
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ment with cysteine and glycine supple-
mentation for 14 days, and this led to
85.1% increase in erythrocyte GSH FSR
(44.86  2.87 vs. 83.03  3.66%/day;
P  0.001), resulting in a 64.4% in-
crease in erythrocyte GSH concentra-
tions (1.65  0.16 vs. 2.72  0.15
mol/g Hb; P  0.001) and a 193.8%
increase in GSH ASR (0.74  0.10 vs.
2.17  0.17 mol GSH/g Hb/day; P 
0.001). Precursor supplementation in-
creased GSH FSR to the level of nondi-
abetic control subjects and led to
signiﬁcant increases in GSH concentra-
tions and GSH ASR. However, when
GSHconcentrationsandASRwerecom-
pared between diabetic subjects and
control subjects diabetic after supplemen-
tation, they remained at 59.7% (2.72 
0.15 vs. 6.75 0.47 mol GSH/g Hb; P
0.001) and 58.7% (0.74 0.10 vs. 5.26 
0.61 mol GSH/g Hb/day; P  0.001)
lower, respectively, in the diabetic subjects
postsupplementation (Figs. 1A–C). Com-
pared with presupplementation values, the
postsupplementationvaluesoferythrocyte
concentrations of GSSG (0.33  0.07 vs.
0.280.07mmol/gHb;PNS)andthe
ratio of GSH to GSSG (6.30  1.30 vs.
12.63  3.15; P  NS) did not change
signiﬁcantly.
Plasma oxidant parameters
The slower rates of GSH synthesis in the
diabetic subjects at baseline were associ-
ated with signiﬁcantly higher concentra-
tions of markers of oxidative damage
(plasmaDROMsandlipidperoxides)(Ta-
ble 1) than in control subjects. After 14
days of cysteine and glycine supplemen-
tation, there was a signiﬁcant fall in these
parameters in the diabetic subjects, al-
though not to the levels observed in the
nondiabetic control subjects.
CONCLUSIONS — The results of
this study demonstrate that intracellular
concentrations of GSH, as well as of its
precursor amino acids cysteine and gly-
cine, are decreased in adult patients with
poorly controlled type 2 diabetes com-
paredwithnondiabeticsubjects.Whereas
previous studies also have found that di-
abetic patients have deﬁcient cellular lev-
els of GSH (3–5), the present data go
further to demonstrate that the GSH deﬁ-
ciency seems to be attributed to a mark-
edly lower synthetic rate of GSH and is
associated with increased oxidant stress
and elevated plasma markers of oxidant
damage. Fourteen days of oral dietary
supplementation with cysteine and gly-
cine in diabetic subjects restored the frac-
tional synthesis rates of GSH to those
observed in nondiabetic control subjects.
This was accompanied by signiﬁcant de-
clines in both oxidative stress and plasma
markers of oxidant damage.
Suboptimal restoration of the abso-
lute synthesis rate of GSH after cysteine
and glycine supplementation, despite full
normalization of its fractional synthesis,
suggests that there is also persistent, ac-
celeratedconsumptionofGSHindiabetic
patients with uncontrolled hyperglyce-
mia. Furthermore, although the levels of
the oxidative stress markers were signiﬁ-
cantlydiminishedafter2weeksofprecur-
sor supplementation, they did not attain
thelowlevelsobservedinthenondiabetic
control subjects. A longer duration of in-
tervention may be required to normalize
synthesisandintracellularconcentrations
of GSH.
GSH is a tripeptide of glutamate, cys-
teine, and glycine, and measurement of
these amino acids within erythrocytes
showed low levels of cysteine and glycine
but not of glutamate. Deﬁciency of cys-
teine and glycine in diabetic humans also
has been reported previously in the liter-
ature (14). Because catabolic processes of
virtually all amino acids cycle through
glutamate production, it is not surprising
that glutamate levels were not different
from those of nondiabetic subjects. The
deﬁciency in cysteine and glycine is in-
Figure 1—A: Erythrocyte GSH concentrations (mol GSH/g Hb). B: GSH fractional synthesis
rate (%/day). C: GSH absolute synthesis rate (mol GSH/g Hb /day). RBC  erythrocytes.
*Control subjects versus diabetes pretreatment, P  0.001; Diabetes pretreatment versus dia-
betes posttreatment, P  0.001).
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traditionally are considered to be “nones-
sential,” meaning that they can be synthe-
sized endogenously. Why are patients
with uncontrolled type 2 diabetes unable
to synthesize cysteine and glycine ade-
quately?Theplasmaﬂuxofanonessential
aminoacidresultsfromthesumofitsrate
of release from protein breakdown, de
novo synthesis, and dietary absorption.
Studies evaluating protein turnover in di-
abetic patients have reported abnormal
overall protein balance (15), and disrup-
tionofmetabolicpathwaysresultingfrom
hyperglycemia could impose higher di-
etary protein requirements (15). Hence, a
combination of impaired protein turn-
over and dietary deﬁciency could under-
lie inadequate availability of cysteine and
glycineforGSHsynthesisintype2diabe-
tes. Additional studies are needed to eval-
uate the mechanisms underlying
decreased availability of cysteine and gly-
cine in type 2 diabetes.
Although the exact mechanisms un-
derlying cysteine and glycine deﬁciency
in type 2 diabetes are not clear, the net
resultofthisdeﬁciencycouldhaveadom-
ino effect leading to oxidative stress and
tissue damage. First, GSH synthesis
would be blunted, and this would result
in a critical imbalance between GSH-
driven antioxidant protection and the
harmfuleffectsofunopposedelevatedox-
idative stress in uncontrolled diabetes.
Deﬁciency of sulfur amino acids (16) or
protein content (17) in the diets of
healthy humans has been previously
shown to result in suppression of GSH
turnover in vivo. Further, animals fed di-
ets speciﬁcally lacking GSH precursor
amino acids, especially cysteine, develop
GSH deﬁciency (18–21). Together with
the present ﬁndings, these data indicate
thatanimportantunderlyingcauseforin-
tracellular GSH deﬁciency in diabetes is
decreased in vivo GSH synthesis because
of a reduced availability of the precursor
amino acids cysteine and glycine.
Could the lower concentrations of
GSH be a result of impaired cycling be-
tween its oxidized and reduced isoforms,
with a greater proportion of glutathione
trapped as the oxidized form? To answer
this question, we also measured concen-
trations of total GSH by converting oxi-
dized glutathione to its reduced isoform
with a reducing agent, and found that
subjects with diabetes still had signiﬁ-
cantly lower concentrations of total gluta-
thione. This suggests that in poorly
controlled type 2 diabetes, there is a true
deﬁciency of glutathione.
Sustained hyperglycemia is linked to
increasedoxidativestress,andwithanin-
creasedriskofdiabeticmicrovascularand
macrovascular complications. Mecha-
nisms implicated in hyperglycemia-
driven tissue damage in diabetes include
abnormal signaling through protein ki-
nase C, elevated advanced glycation end
products, and the aldose reductase path-
way (1). ROS is known to stimulate these
pathways by activation of aldose reduc-
tase, protein kinase C isoforms, and nu-
clear factor-	B and induction of
diacylglycerol and advanced glycation
end-product formation (22). Lowering
levels of mitochondrial ROS (and thereby
oxidative stress) successfully prevents ac-
tivation and induction of these mecha-
nisms (23). Because ROS production is
increased by hyperglycemia, optimizing
glycemic control in diabetic subjects
should decrease ROS, but, in clinical
practice, normalizing glycemia remains a
major challenge in diabetes management.
It is estimated that up to 55% of diabetic
patients in the U.S. do not attain the
American Diabetes Association’s recom-
mended glycemic goals, and 67% do not
attain the more stringent glycemic targets
of the American Association of Clinical
Endocrinologists. Therefore, interven-
tions directly aimed at lowering ROS-
mediated oxidative stress are needed to
preventdiabetictissuedamageeveninthe
presence of hyperglycemia. The present
data suggest that increasing GSH levels
with oral precursor supplementation is a
viable intervention to target diabetic oxi-
dative stress directly and could constitute
a novel, safe, and inexpensive form of nu-
tritional treatment. When used as an ad-
junct to standard glycemic management,
this approach could signiﬁcantly attenu-
ate tissue damage due to oxidative stress
in patients with diabetes.
In conclusion, these data show that
an important reason underlying elevated
oxidative stress in type 2 diabetes is deﬁ-
ciency of glutathione, which occurs be-
cause of the decreased synthesis caused
by limited availability of the precursor
amino acids cysteine and glycine. Dietary
supplementation of these amino acid pre-
cursors restores fractional synthesis of
GSH and signiﬁcantly reduces oxidative
stress and markers of oxidant damage.
Providing supplemental cysteine and gly-
cine in the diet could be a safe, inexpen-
sive, and innovative approach to increase
GSH synthesis and concentrations and
thus combat oxidative stress and prevent
chronic complications in patients with
diabetes.
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